Research paper: Dalteparin as a novel therapeutic agent to prevent diabetic encephalopathy by targeting oxidative stress and inflammation by Zeinivand, M. et al.
Basic and Clinical
795
November, December 2020, Volume 11, Number 6
Research Paper: Dalteparin as a Novel Therapeutic Agent 
to Prevent Diabetic Encephalopathy by Targeting Oxidative 
Stress and Inflammation
Motahareh Zeinivand1 , Arezo Nahavandi2* , Tourandokht Baluchnejadmojarad2 , Mehrdad Roghani3 , Fereshteh Golab4  
1. Department of Physiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
2. Department of Physiology, School of Medicine, Iran University of Medical Sciences, Iran, Iran.
3. Department of Physiology, School of Medicine, Shahed University, Tehran, Iran.
4. Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
* Corresponding Author: 
Arezo Nahavandi, PhD.
Address: Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Tel: +98 (918) 3449497
E-mail: arezonahavandi_1999@yahoo.com
Introduction: Hepcidin is the main modulator of systemic iron metabolism, and its role in the 
brain has been clarified recently. Studies have shown that hepcidin plays an important role in 
neuronal iron load and inflammation. This issue is of significance because neuronal iron load 
and inflammation are pathophysiological processes that are highly linked to neurodegeneration. 
Moreover, the activity of hepcidin has recently been manipulated to recover the neuronal 
impairment caused by brain inflammation in animal models.
Methods: Streptozotocin (STZ) was used to induce type 1 diabetes. Male Wistar rats (n = 
40) with a weight range of 200–250 g were divided into control, diabetic, diabetic + insulin, 
and diabetic + dalteparin groups. Dalteparin (100 mg/kg IP) and insulin (100 mg/kg SC) were 
administered for 8 weeks. At the end of the experiment, Y-maze and passive avoidance tasks 
were carried out. The animals were perfused randomly and their hippocampal tissue was 
isolated for the analysis of markers such as lipid peroxidation like Malondialdehyde (MDA), 
hepcidin expression, iron, and ferritin. Blood samples were taken for the measurement of 
serum inflammatory cytokine Interleukin (IL)-6.
Results: The findings indicated that treatment with dalteparin reduced IL-6, MDA, ferritin, and 
hepcidin expression in diabetic rats compared to treatment with insulin (P<0.05). Moreover, 
treatment with dalteparin did not decrease the iron level or prevented its decline.
Conclusion: Treatment with dalteparin improved the cognitive dysfunctions and symptoms 
of Alzheimer disease in STZ-induced diabetic rats by appropriately modulating and reducing 
oxidative stress and neuroinflammation. This may enhance the existing knowledge of 
therapeutics to reduce cognitive impairment in diabetes and is suggested to be a potential 
therapeutic agent in diabetes.
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1. Introduction
esearchers have recently proposed the term 
type 3 diabetes for Alzheimer Disease (AD) 
owing to the molecular and cellular features 
shared among type 1 diabetes, diabetes-
related memory dysfunction, and cognitive 
impairment in the elderly. Chronic diabetes 
is associated with impaired learning, memory loss, at-
tention dysfunction, and dementia (Kumar Datusalia & 
Sunder Sharma, 2016). Enhanced oxidative stress and 
inflammatory condition in the diabetic brain are also 
considered important pathogenic factors in the cogni-
tive decline of diabetes (Ma et al., 2015). Recently, it 
has been shown that diabetes is an inflammatory con-
dition associated with iron abnormalities and increased 
oxidative damage (Van Campenhout et al., 2006). Iron 
homeostasis is a main factor in sustaining the function 
of the Central Nervous System (CNS) and an essential 
element involved in the modulation of oxygen transport, 
neurotransmission, myelination, and neuronal metabo-
lism (Murray & Lynch, 1998). However, iron imbal-
ance and atypical build-up in the CNS are indicative of 
neuroinflammation and are involved in several neurode-
generative disorders (Ward, Zucca, Duyn, Crichton, & 
Zecca, 2014). A lot of evidence supports the idea that 
iron regularly builds up in the brain with age increase, 
oxidative stress, cell death, and neurotoxicity (Murray 
& Lynch 1998). Iron promotes the free radical forma-
tion and oxidative stress, which can trigger a cascade 
of harmful events that lead to neurodegeneration (Ke & 
Qian, 2007). Hepcidin is the primary regulator of iron 
homeostasis in the body and is mainly expressed in the 
liver (Nicolas et al., 2001). Many studies have also re-
ported a large distribution of this peptide in the brain 
(Wang et al., 2008). Recent research has shown that iron 
dysmetabolism in the brain can be managed by the ma-
nipulation of hepcidin because the production of hepci-
din in the brain has been reported to influence cellular 
iron transport (Xiong et al., 2016; Zhou et al., 2017). 
Yet, the presence or absence of inflammation appears to 
dictate the harmful vs. useful properties of hepcidin in 
the brain (Vela, 2018). In peripheral organs, the elevated 
level of hepcidin will lead to a lower iron level by con-
trolling intestinal iron absorption, iron recycling in mac-
rophages, iron mobilization from hepatic stores, and iron 
utilization in bone marrow cells (Park, Valore, Waring, & 
Ganz, 2001). A recent investigation showed that manipu-
lation hepcidin has a role in reducing iron in the brain 
by down-regulating iron-transport proteins (Vela 2018). 
Thus, we hypothesized that an anti-hepcidin (dalteparin) 
agent might stop iron accumulation and decrease iron-
induced oxidative stress. The current research tested this 
hypothesis and showed that treatment of diabetic rats 
with dalteparin decreased hepcidin expression and pre-
vented the increased iron content and reactive oxygen 
species in the brain of diabetic rats.
2. Methods
2.1. Study design
This experimental research aimed to compare the ef-
fect of dalteparin (anti-hepcidin) and insulin treatment 
on cognitive dysfunction, learning, and memory impair-
ment due to type 1 diabetes. The study protocol was 
Highlights 
● Treatment with dalteparin improved the cognitive dysfunctions and symptoms of Alzheimer’s disease in STZ-
induced diabetic.
● This is applicable by appropriately modulating and reducing oxidative stress and neuroinflammation. 
● This may promote the existing knowledge of therapeutics to reduce cognitive impairment in diabetes and may be 
a proper substitute to insulin therapy.
Plain Language Summary 
Hepcidin is the principal modulator of systemic iron metabolism, and its role in the brain has been clarified recently. 
Studies have shown hepcidin plays a twofold role for in neuronal iron load and inflammation. The findings indicated 
that treatment with dalteparin (anti-hepcidin) improved the cognitive dysfunctions in STZ-induced diabetic rats by ap-
propriately modulating and reducing oxidative stress and neuroinflammation. This may include therapeutics to reduce 
cognitive impairment in diabetes and maybe a proper substitute for insulin therapy.
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approved by Iran University of Medical Sciences. The 
researchers followed the principles of the Helsinki Dec-
laration and the principles of using laboratory animals 
as proposed in the National Institutes of Health Guide 
for Care and Use of Laboratory Animals during the 
study. Most of the materials were prepared from Sigma-
Aldrich Company, Germany. The relevant company is 
given for each material.
2.2. Study animals
Male Wistar rats (n = 40) with a weight range of 200–
250 g were obtained from the Laboratory Animal Breed-
ing Center of Iran University of Medical Sciences and 
randomly classified into four groups (10 animals in each 
group) of control (healthy animals without treatment), 
diabetic group, diabetic + insulin, and diabetic + dalte-
parin groups. All animals were kept in special cages for 
a minimum of 2 weeks before the start of the experiment 
to adapt to the environment. They were provided with 
water and food ad libitum (temperature 21°C±1°C; 12-h 
light/dark cycle). All behavioral tests were conducted 
from 10:00 AM to 2:00 PM at room temperature. The 
study groups included control, diabetic, insulin-treated 
diabetic, and dalteparin-treated diabetic. Diabetes was 
induced by a single intraperitoneal administration of 
60 mg/kg Streptozotocin (STZ) (Sigma Aldrich, USA) 
which was freshly dissolved in cold normal saline. 
One week following STZ administration, fasting blood 
samples were taken from the tail vein overnight and col-
lected under light ether anesthesia. Serum glucose con-
centrations were measured by the glucose oxidase tech-
nique (Zistshimi, Tehran). Only rats with a fasting serum 
glucose level above 250 mg/dL were considered to be 
diabetic. Intraperitoneal administration of dalteparin 
(100 mg/kg/d) was initiated 1 week after STZ injection 
for 8 weeks. The dose of dalteparin was chosen based 
on previous research on the anti-inflammation and an-
tioxidant effects of dalteparin (Farajdokht et al., 2015). 
Insulin (1.5 IU/ kg/d) (Caret, Bougnères, et al. 1996) was 
administered subcutaneously 1 week after STZ injection 
in the insulin group for 8 weeks. 
2.3. Behavioral evaluations
Behavioral tests, including the Y-maze task and passive 
avoidance test, were performed 8 weeks after the induc-
tion of type 1 diabetes. 
2.4.Y-maze test 
Y-maze paradigm is a reliable and non-invasive behav-
ioral test that is used to measure spatial working memory 
in rodents through evaluation of spontaneous alternation 
behavior (Kalalian-Moghaddam, Baluchnejadmojarad, 
Roghani, Goshadrou, & Ronaghi, 2013). The Y-maze 
comprises 3 arms and an equilateral triangular central 
area. All rats were tested once in a randomized order. 
They were placed at the end of 1 arm and permitted to 
make a move freely through the maze for 8 minutes. An 
arm entry was counted when the rat’s hind paws were in 
the arm completely. Alternation was defined as consecu-
tive entries into the 3 arms on the overlapping triplet sets 
(i.e. A, B, C or B, C, A, etc.). The number of maximum 
spontaneous alternations was then determined as the to-
tal number of arm entries minus 2, and the percentage 
was computed as the ratio of actual/possible alternations 
(defined as the total number of arm entries minus 2). 
Besides, the total number of arm entries was utilized as 
an index for general locomotive activity. The maze was 
cleaned with 70% ethanol between sessions to eliminate 
the odor cues of compounds. The Y-maze task was per-
formed on day 51 after STZ administration.
2.5. Passive Avoidance test
This test was performed by the shuttle box apparatus 
(BPT Co., Tehran) based on a former study with some 
changes applied (Roghani, Joghataie, Jalili, & Baluchne-
jadmojarad, 2006). The shuttle box consists of two com-
partments, one lighted chamber, and one dark chamber, 
with a grid floor connected by a guillotine door. Electric 
shock was applied by an isolated stimulator. On the first 
and second days, each rat was put into the apparatus and 
left there for 5 min to explore the chambers and adapt to 
the environment. During the acquisition test (the third 
day), the rats were put in the lighted chamber and after 
5 min adaptation period, the guillotine door was opened 
and the latency to enter the dark chamber was record-
ed. Following the rat’s entry into the dark chamber, the 
door was closed and an electric foot shock (1 mA, 1 s) 
was applied to the grid floor. On the acquisition day, the 
Initial Latency (IL) of entry into the dark chamber was 
recorded, and rats with ILs of above 60 s were exclud-
ed from the study. Twenty-four hours later, a retention 
test was conducted and the interval between placement 
in the lighted chamber and entry into the dark chamber 
was calculated as Step-Through Latency (STL up to a 
maximum of 480 s as a cut-off point). Passive avoidance 
task was performed from day 52 to day 55 after STZ 
administration.
2.6. Determination of hippocampal oxidative stress
At the end of week 8 following STZ administration, hippo-
campal tissue was dissected out separately and 10% homog-
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enate was prepared in ice-cold normal saline containing 0.1% 
Triton X100 and protease inhibitor cocktail. The obtained su-
pernatant was aliquoted and kept at -70°C for the following 
experiments (Baluchnejadmojarad, Kiasalari, Afshin-Ma-
jd, Ghasemi, & Roghani, 2017). Malondialdehyde (MDA) 
level, the biological marker of lipid peroxidation due to oxida-
tive stress, was determined in the supernatant as described pre-
viously (Kalalian-Moghaddam et al., 2013). To determine 
MDA concentration, trichloroacetic acid and TBARS (Thio-
barbituric acid reactive substances) reagent were added to the 
supernatant and then mixed and incubated at boiling water for 
90 min. The samples were centrifuged at 1000 g for 10 min 
after cooling on ice, and the absorbance rate of the supernatant 
was read at 532 nm. The findings were obtained on the stan-
dard curve of tetraethoxypropane. 
2.7. Serum interleukin-6 measurements
Having conducted the last behavioral tests, the animals 
were deeply anesthetized and sacrificed from 10:00 to 
12:00 AM. Then, their blood samples were collected, and 
serum Interleukin (IL)-6 concentration was determined 
by Enzyme-Linked Immunosorbent Assay (ELISA) kits 
(eBioscience) based on the manufacturer’s instructions.
2.8. Hippocampal iron and ferritin measurement
After performing the last behavioral tests, the animals 
were deeply anesthetized and sacrificed between 10:00 
and 12:00 AM. The hippocampal tissue was then dissect-
ed out separately, and the acquired supernatant was ali-
quoted and kept at -70°C for the following experiments. 
Next, the concentration of iron and ferritin in the tissue 
sample was determined by Enzyme-Linked Immuno-
sorbent Assay (ELISA) kits (eBioscience) based on the 
manufacturer’s guidelines.
2.9. Real-Time PCR
Hippocampal total RNA was isolated by Trizol Reagent 
(Roche) and alcohol-chloroform protocol according to the 
manufacturer’s instructions. Total RNA was reverse tran-
scribed in a 25_l reaction using QuantiTec reverse tran-
scription cDNA kits (Qiagen). Reactions were analyzed by 
QuantiFast SYBR Green PCR kit and a special primer pair 
for hepcidin cDNA and genomic DNA sequences of beta-
actin. Primers were as follows: hepcidin forward 5/- TT-
GCGATACCAATGCAGAAGAG-3/and reverse 5/-AATT-
GTTACAGCATTTACAGCAGAAGA-3/, for the _-actin 
forward 5/- AGGCCCAGAGCAAGAGAGGTA-3/and re-
verse 5/-TCTCCATGTCGTCCCAGTTG-3/.
2.10. Statistical analysis
Data were analyzed by SPSS (version 21.0) and reported as 
the mean and standard error. One-way ANOVA and Bonfer-
roni post hoc tests were used to compare the data. P<0.05 
was considered significant for all analyses.
3. Results
3.1. Diabetic induced condition affecting body 
weight and serum glucose level
Induction of diabetes significantly decreased the body 
weight compared to the control group (df: 3, F=55.70; 
P<0.001). These alterations were reduced by dalteparin 
therapy (P<0.05) and insulin therapy (P<0.05). Further, no 
significant correlation was found between the insulin- and 
dalteparin-treated groups. This finding suggests that diabetes 
is strongly associated with lower body weight (Figure 1).
Figure 2. Serum glucose concentration in different groups 
(Mean±SEM)
*** P<0.001 (compared to the diabetic group); #P<0.05; ## 
P<0.01; ###P<0.001 (compared to the control group) (n=8–10 
for each group).
Figure 1. Body weight in different groups (Mean±SEM)
*P<0.05 (compared to the diabetic group); ###P<0.001 (com-
pared to the control group) (n=8–10 for each group). 
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Moreover, induction of diabetes significantly increased 
serum glucose level compared to the control group (df: 3, 
F=33.05; P<0.001) (Figure 2). These changes were dimin-
ished by dalteparin therapy (P<0.01) and insulin therapy 
(P<0.05). Additionally, no significant correlation was ob-
served between the insulin- and dalteparin-treated groups. 
This indicates that dalteparin has anti-diabetic effects.
3.2. Diabetes induction affects iron and ferritin levels 
in the hippocampus 
We assessed the effect of diabetes on hippocampal iron ho-
meostasis. Induction of diabetes over 8 weeks caused iron 
accumulation in the hippocampus compared to the control 
group (df: 3, F=30.03; P<0.001) (Figure 3). Treatment with 
dalteparin and insulin showed no difference in hippocampal 
iron levels compared to diabetic rats.
To confirm these alterations, the ferritin level was measured 
as the main parameter for intracellular iron level in the hip-
pocampus. Induction of diabetes significantly increased fer-
ritin level compared to the control group (df: 3, F=124.02; 
P<0.001) (Figure 4). These changes decreased as a result of 
treatment with dalteparin (P<0.001) and insulin (P<0.01) 
compared to the diabetic group. Besides, the results are indic-
ative of the better efficacy of dalteparin than insulin in reduc-
ing ferritin level and restoring it to control levels (P<0.01).
We measured the protein expression of key components 
in hippocampal iron homeostasis, hepcidin. Compared to 
the control, diabetes caused a significant increase in hepci-
din in the hippocampus following the induction of diabe-
tes over 8 weeks (df: 3, F=12.5; P<0.01) (Figure 5). Fur-
thermore, treatment with dalteparin significantly reduced 
diabetic-induced alterations in hepcidin level (P<0.01), 
suggesting that dalteparin is associated with decreased 
hepcidin content in the brain.
3.3. Dalteparin prevents inflammation and oxida-
tive stress in the hippocampus 
Induction of diabetes during 8 weeks significantly 
increased hippocampal IL-6 level (df: 3, F=35.36; 
P<0.001) (Figure 6). These changes were low as a re-
sult of treatment with dalteparin compared to the dia-
betic and insulin groups (P<0.01). There was also a 
significant correlation between hippocampal iron 
content and IL-6 level. Furthermore, the iron con-
tent in the brain highly affects neuroinflammation. 
In addition to neuroinflammation and oxidative stress 
markers, hippocampal MDA levels significantly in-
creased in the diabetic group compared to the control 
group (df: 3, F=16.84; P<0.001) (Figure 7), which was 
significantly diminished by the treatment with dalteparin 
(P<0.001) in comparison with the insulin therapy.
3.4. Dalteparin prevents memory impairments
Y-maze and passive avoidance tests were used to assess 
cognitive function in diabetic rats. In the Y-maze task 
which indicated short-term spatial recognition memory, 
a significant reduction was found in alternation behavior 
(%) after induction of diabetes compared to the control 
group (df: 3, F=55.32; P<0.001) (Figure 8A). This ef-
fect was significantly attenuated by the treatment with 
dalteparin (P<0.001). These findings indicate the better 
impact of dalteparin compared to insulin in facilitating 
learning and restoring memory function. Moreover, the 
total number of arm entries in Y-maze showed that the 
diabetic group significantly spent less time in arm entries 
than the control group (df: 3, F=8.82; P<0.05) (Figure 
8B), indicating that treatment with dalteparin had no sig-
nificant impact on the locomotors activity.
Figure 3. Iron level in serum in different groups (Mean±SEM)
###P<0.001 (compared to the control group); (n=8–10 for 
each group).
Figure 4. Ferritin level in serum in different groups 
(Mean±SEM)
###P<0.001 (compared to the control group), **P<0.01, *** 
P<0.001 (compared to the diabetic group); $ P<0.05 (com-
pared to the insulin group) (n=8–10 for each group).
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In the passive avoidance task, a significant decrease was 
observed in Step-Through Latency (STL) after the in-
duction of diabetes in comparison with the control group 
(df: 3, F=7.58; P<0.001) (Figure 9). Treatment with 
dalteparin significantly boosted STL compared to the di-
abetic group (P<0.05) and insulin group (P<0.05), indi-
cating that dalteparin reduced diabetic-induced memory 
impairment. No differences were found between groups 
in Initial Latency (IL) (data are not shown).
4. Discussion
The primary purpose of the current study was to find 
out whether dalteparin (an anti-hepcidin agent) might 
prevent the cognitive dysfunction caused by type 1 dia-
betes or not. The findings indicated a better control of 
diabetes by dalteparin than by insulin. Dalteparin has 
both antioxidant and anti-inflammatory effects on dia-
betic subjects. In T1DM, poor performance was reported 
for STZ-induced diabetic rats in passive avoidance func-
tions (Nasri, Roghani, Baluchnejadmojarad, Balvardi, & 
Rabani, 2012). The partially positive impact of daltepa-
rin on the improvement of memory could be related to 
its ability in improving chronic hyperglycemia, which is 
linked to most problems of diabetes, including cognitive 
dysfunctions (Kalalian-Moghaddam et al., 2013). Dalte-
parin can also inhibit hepatic gluconeogenesis (Vecchi et 
al., 2014). According to study results, the oral glucose 
tolerance test indicates an increase in serum hepcidin lev-
els and a decrease in serum iron concentrations in healthy 
individuals (Chand, Singh, Pendharkar, & Petrov, 2018). 
Scientists have suggested that glucose probably plays 
a modulatory role in serum iron concentrations. On the 
other hand, the anti-hepcidin properties of dalteparin may 
exert anti-diabetic effects.
In agreement with other studies, the present study 
showed a significant elevation in the hippocampal MDA 
of diabetic rats. Sustained hyperglycemia is believed to 
be the main moderator for the elevated production of 
reactive oxygen species (Di Marco et al., 2015). The 
increased MDA concentration shows oxidative injury 
(Baluchnejadmojarad et al., 2017), which is involved in 
the development of a diabetic impaired brain (Baluchne-
jadmojarad et al., 2017). Iron is the main factor involved 
in the production of reactive oxygen species through 
the Fenton reaction, indicating that excessive iron is too 
toxic for neurons (Gong et al., 2016). Moreover, lipid 
and protein molecules in the cell membrane and intra-
cellular structures may be impaired by the catalysis of 
hydroxyl radicals by iron and the generation of highly 
active free radicals (Hatunic et al., 2010). Cognitive im-
pairment in diabetic individuals has been reported to be 
Figure 5. Hepcidin mRNA expression in different groups 
(Mean±SEM)
***P<0.001 (compared to the diabetic group); ###P<0.001 (com-
pared to the control group) (n=8–10 for each group).
Figure 6. Interleukin-6 concentration in the hippocampus in 
different groups (Mean±SEM)
**P<0.01 (compared to the diabetic group); ###P<0.001 (com-
pared to the control group), $$ P<0.01 (compared to the insu-
lin group) (n=8–10 for each group). 
Figure 7. MDA concentration in different groups 
(Mean±SEM)
*** P<0.001 (compared to the diabetic group); ## P<0.01, 
### P<0.001 (compared to the control group), $$ P<0.01 
(compared to the insulin group) (n=8–10 for each group).
Zeinivand, M., et al. (2020). Dalteparin to Prevent Diabetic Encephalopathy, Stress and Inflammation. BCN, 11(6), 795-804.
Basic and Clinical
801
November, December 2020, Volume 11, Number 6
associated with iron overload in the brain and oxidative 
damage (Ward, Zucca et al. 2014; Garton et al., 2016). 
A study showed that iron played a pathophysiologic role 
in neurodegenerative conditions (Ward et al., 2014), AD 
(Smith, Harris, Sayre, & Perry, 1997), PD (Parkinson 
Disease) (Berg et al., 2001), and many other neurode-
generative dysfunctions (Dwyer et al., 2009). The pres-
ent research indicated a reduction in MDA levels in the 
brain of dalteparin-treated rats compared with other dia-
betic groups, indicating the better antioxidant effect of 
dalteparin than insulin. Unlike dalteparin, insulin failed 
to control oxidative stress.
Hepcidin is the main moderator of systemic iron ho-
meostasis (Vela 2018). Hepcidin hinders the expression 
of iron-uptake proteins in the brain (Du, Qian, Luo, Yung, 
& Ke, 2015). The uptake proteins interfere with “Fpn1-
mediated” iron release in both astrocytes and neurons 
(Du et al., 2015). Down-regulation of Fpn1 by hepcidin 
elevates intracellular iron concentration and probably re-
duces the expression of uptake proteins. Any disturbance 
in the expression of iron transport protein causes an iron 
imbalance in the brain (Gong et al., 2016). In T1DM, up-
regulation of hepcidin occurs due to iron overload fol-
lowing oxidative stress and inflammatory process (Ganz 
& Nemeth, 2012). In the pathogenesis of diabetes, iron 
plays a diabetic and a causal role in the failure of beta-
cell, insulin resistance, and tissue dysfunction (Backe, 
Moen, Ellervik, Hansen, & Mandrup-Poulsen, 2016). In 
the current study, dalteparin seems to have ameliorated 
cognitive dysfunction by decreasing the expression of 
hepcidin as a result of reduced iron load.
Hepcidin gene expression terminates the overexpres-
sion of the hepcidin gene at low levels of iron (Poli et 
al., 2014). This study was the first to report the decreased 
expression of the hepcidin gene by dalteparin in T1DM. 
Unlike dalteparin, insulin could not reduce hepcidin ex-
pression in T1DM, which might explain why cognitive 
parameters were exacerbated in the insulin group. Dalte-
parin has been reported to have inhibitory effects on the 
expression of hepcidin during inflammatory conditions 
(Poli et al., 2014). In line with the findings of the present 
study, other studies have shown that insulin directly reg-
ulates hepcidin, and hepcidin is considerably involved 
in iron overload in STZ-induced diabetic rats (Wang, 
Li, Jiang, Shi, Shen, & Li 2014). Hyperglycemia may 
also play a role in the regulation of hepcidin (Aigner et 
Figure 8. Y-maze and passive avoidance tests used to assess cognitive function in diabetic rats 
A. Alternation behavior in Y-maze task in different groups (Mean±SEM); ** P<0.01 (compared to the diabetic group); # P<0.05, 
### P<0.001 (compared to the control group), $ P<0.05 (compared to the dalteparin group) (n=8–10 for each group).
B. Total number of arms entrance in Y-maze task in different groups (Mean±SEM); # P<0.05 (compared to the control group), 
(n=8–10 for each group).
A B
Figure 9. Step through latencies in single-trial passive 
avoidance task in different groups (Mean±SEM)
*P<0.05, ***P<0.001 (compared to the diabetic group); 
#P<0.05; ###P<0.001 (compared to the control group), 
$P<0.05 (compared to the dalteparin group) (n=8–10 for 
each group).
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al., 2013). Oral glucose tolerance test has recently been 
reported to increase serum hepcidin even in healthy indi-
viduals (Aigner et al., 2013). Another finding of the cur-
rent study was the increased iron level in hippocampal 
tissue in T1DM. However, dalteparin could not modify 
this iron overload. Iron (extracellular iron) sedimentation 
of tissue in T1DM is mainly caused by impaired blood-
brain barrier due to inflammation (Vela, 2018). On the 
other hand, iron sediment in the tissue must be cleaned 
by hepcidin, which is inhibited by dalteparin. Therefore, 
high levels of iron in hippocampal tissue cannot be regu-
lated by dalteparin.
Furthermore, dalteparin reduced hippocampal ferritin 
levels, which is contrary to the above results. To explain 
this contradiction, it should be noted that ferritin is the 
major parameter of “intercellular iron level”. Hepcidin el-
evates intracellular iron and dalteparin hinders hepcidin, 
thereby preventing the increase of intracellular iron. Epi-
demiologic and clinical studies have shown that diabetic 
people are more vulnerable to AD (Crane et al., 2013). 
STZ-induced diabetes in rats causes inflammatory con-
ditions and elevates pro-inflammatory and inflammatory 
cytokines. Neurovascular inflammation is mostly caused 
by tumor necrosis factor-alpha and IL-6, which contrib-
utes to synaptotoxicity and neurodegeneration (Matrone, 
Djelloul, Taglialatela, & Perrone, 2015). Also, strong 
clues indicate the modulatory activities of hepcidin fol-
lowing brain inflammatory conditions (Vela, 2018). IL-6 
regulation hepcidin synthesis and dalteparin can suppress 
IL-6 levels in inflammatory conditions, which reduces 
the increase in hepcidin (Zhang et al., 2017). It is con-
spicuous that both local and or systemic hepcidin are 
elevated during brain inflammation, which consequently 
brings about iron overload (Zhang et al., 2017). Hepcidin 
functions as a double-edged sword that reduces intercel-
lular iron overload through iron transfer to intracellular 
space to deal with inflammation (Zhao et al., 2018).
In conclusion, treatment with dalteparin prevents cog-
nitive impairments in STZ-induced diabetic rats. Hence, 
it may be suggested as a therapeutic agent to control the 
adverse effects of T1DM.
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